Free Trial
LON:HCM

HUTCHMED (HCM) Share Price, News & Analysis

HUTCHMED logo
GBX 246 -1.00 (-0.40%)
(As of 11:48 AM ET)

About HUTCHMED Stock (LON:HCM)

Key Stats

Today's Range
241
248
50-Day Range
229
323
52-Week Range
190.40
353
Volume
29,947 shs
Average Volume
37,037 shs
Market Capitalization
£2.10 billion
P/E Ratio
N/A
Dividend Yield
4.63%
Price Target
N/A
Consensus Rating
N/A

Company Overview

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.

Receive HCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HUTCHMED and its competitors with MarketBeat's FREE daily newsletter.

HCM Stock News Headlines

Hutchmed divests 45% interest in Shanghai Hutchison for $608M
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture
HUTCHMED Divests 45% Stake In Shanghai Hutchison Pharmaceuticals For $608 Mln
See More Headlines

HCM Stock Analysis - Frequently Asked Questions

HUTCHMED's stock was trading at GBX 235 at the beginning of 2025. Since then, HCM shares have increased by 4.7% and is now trading at GBX 246.
View the best growth stocks for 2025 here
.

Shares of HCM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that HUTCHMED investors own include Intelsat (I), Associated British Foods (ABF), Chaarat Gold (CGH), Bank of America (BAC), Fossil Group (FOSL), AMC Entertainment (AMC) and Air Canada (AC).

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
Pharmaceutical Products
CIK
N/A
Fax
N/A
Employees
1,760
Year Founded
N/A

Profitability

Net Income
£-41,970,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£610.81 million
Cash Flow
GBX 98.60 per share
Book Value
GBX 87 per share

Miscellaneous

Free Float
N/A
Market Cap
£2.10 billion
Optionable
Not Optionable
Beta
0.76
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (LON:HCM) was last updated on 1/3/2025 by MarketBeat.com Staff
From Our Partners